토브라마이신 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "토브라마이신" in Korean language version.

refsWebsite

Global rank Korean rank

11nih.gov

4^th place

5doi.org

2^nd place

3^rd place

2drugs.com

399^th place

141^st place

2medicines.org.uk

3,823^rd place

2,321^st place

2clincalc.com

3,912^th place

2,490^th place

1tga.gov.au

3,984^th place

1,245^th place

1canada.ca

1,712^th place

1,155^th place

1toku-e.com

low place

1books.google.com

3^rd place

9^th place

1handle.net

102^nd place

307^th place

1web.archive.org

1^st place

1europa.eu

68^th place

145^th place

1semanticscholar.org

11^th place

310^th place

1jstor.org

26^th place

70^th place

1archive.org

6^th place

18^th place

1health.kr

low place

2,285^th place

archive.org (Global: 6^th place; Korean: 18^th place)

Pedersen SS, Jensen T, Osterhammel D, Osterhammel P (April 1987). “Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis”. 《Antimicrobial Agents and Chemotherapy》 31 (4): 594–9. doi:10.1128/AAC.31.4.594. PMC 174783. PMID 3606063.

books.google.com (Global: 3^rd place; Korean: 9^th place)

Fischer J, Ganellin CR (2006). 《Analogue-based Drug Discovery》 (영어). John Wiley & Sons. 507쪽. ISBN 978-3-527-60749-5.

canada.ca (Global: 1,712^th place; Korean: 1,155^th place)

“Product monograph brand safety updates”. 《Health Canada》. February 2024. 2024년 3월 24일에 확인함.

clincalc.com (Global: 3,912^th place; Korean: 2,490^th place)

“The Top 300 of 2021”. 《ClinCalc》. 2024년 1월 15일에 원본 문서에서 보존된 문서. 2024년 1월 14일에 확인함.
“Tobramycin - Drug Usage Statistics”. 《ClinCalc》. 2024년 1월 14일에 확인함.

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, Lorber RR (May 1983). “Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin”. 《Lancet》 1 (8334): 1123–6. doi:10.1016/S0140-6736(83)92864-7. PMID 6133153. S2CID 8303933.
Neu HC (August 1976). “Tobramycin: an overview”. 《The Journal of Infectious Diseases》 134 (Suppl): S3–19. doi:10.1093/infdis/134.supplement_1.s3. JSTOR 30106949. PMID 787451.
Pedersen SS, Jensen T, Osterhammel D, Osterhammel P (April 1987). “Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis”. 《Antimicrobial Agents and Chemotherapy》 31 (4): 594–9. doi:10.1128/AAC.31.4.594. PMC 174783. PMID 3606063.
Yang G, Trylska J, Tor Y, McCammon JA (September 2006). “Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies”. 《Journal of Medicinal Chemistry》 49 (18): 5478–90. doi:10.1021/jm060288o. PMID 16942021.
Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu M, 외. (April 2002). “Design of novel antibiotics that bind to the ribosomal acyltransfer site”. 《Journal of the American Chemical Society》 124 (13): 3229–37. doi:10.1021/ja011695m. PMID 11916405.

drugs.com (Global: 399^th place; Korean: 141^st place)

“Tobramycin Use During Pregnancy”. 《Drugs.com》. 2019년 11월 11일. 2020년 4월 28일에 확인함.
“Tobramycin ophthalmic Use During Pregnancy”. 《Drugs.com》. 2019년 12월 24일. 2020년 4월 28일에 확인함.

europa.eu (Global: 68^th place; Korean: 145^th place)

ema.europa.eu

“Tobi Podhaler”. 《European Medicines Agency (EMA)》. 2018년 9월 17일. 2020년 4월 28일에 확인함. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.

handle.net (Global: 102^nd place; Korean: 307^th place)

hdl.handle.net

World Health Organization (2023). 《The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)》. Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

health.kr (Global: low place; Korean: 2,285^th place)

“토브라주100mg”. 《약학정보원》. 2024년 5월 12일에 확인함.

jstor.org (Global: 26^th place; Korean: 70^th place)

Neu HC (August 1976). “Tobramycin: an overview”. 《The Journal of Infectious Diseases》 134 (Suppl): S3–19. doi:10.1093/infdis/134.supplement_1.s3. JSTOR 30106949. PMID 787451.

medicines.org.uk (Global: 3,823^rd place; Korean: 2,321^st place)

“Tobramycin 40mg/ml Injection – Summary of Product Characteristics (SmPC)”. 《(emc)》. 2018년 10월 9일. 2020년 4월 28일에 확인함.
“Tobradex Eye Drops – Summary of Product Characteristics (SmPC)”. 《(emc)》. 2020년 1월 21일. 2020년 4월 28일에 확인함.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, Lorber RR (May 1983). “Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin”. 《Lancet》 1 (8334): 1123–6. doi:10.1016/S0140-6736(83)92864-7. PMID 6133153. S2CID 8303933.
Neu HC (August 1976). “Tobramycin: an overview”. 《The Journal of Infectious Diseases》 134 (Suppl): S3–19. doi:10.1093/infdis/134.supplement_1.s3. JSTOR 30106949. PMID 787451.
Pedersen SS, Jensen T, Osterhammel D, Osterhammel P (April 1987). “Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis”. 《Antimicrobial Agents and Chemotherapy》 31 (4): 594–9. doi:10.1128/AAC.31.4.594. PMC 174783. PMID 3606063.
Reyhanoglu G, Reddivari AK (January 2022). 〈Tobramycin〉.《StatPearls》. Treasure Island (FL): StatPearls Publishing. PMID 31869159.
Yang G, Trylska J, Tor Y, McCammon JA (September 2006). “Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies”. 《Journal of Medicinal Chemistry》 49 (18): 5478–90. doi:10.1021/jm060288o. PMID 16942021.
Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu M, 외. (April 2002). “Design of novel antibiotics that bind to the ribosomal acyltransfer site”. 《Journal of the American Chemical Society》 124 (13): 3229–37. doi:10.1021/ja011695m. PMID 11916405.

dailymed.nlm.nih.gov

“Tobramycin- tobramycin sulfate injection, powder, for solution”. 《DailyMed》. 2019년 10월 11일. 2020년 4월 28일에 확인함.
“Tobi- tobramycin solution”. 《DailyMed》. 2018년 10월 5일. 2020년 4월 28일에 확인함.
“Tobrex- tobramycin ointment”. 《DailyMed》. 2019년 9월 16일. 2020년 4월 28일에 확인함.
“Tobradex- tobramycin and dexamethasone ointment”. 《DailyMed》. 2019년 9월 11일. 2020년 4월 28일에 확인함.
“Tobradex- tobramycin and dexamethasone suspension/ drops”. 《DailyMed》. 2019년 9월 9일. 2020년 4월 28일에 확인함.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, Lorber RR (May 1983). “Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin”. 《Lancet》 1 (8334): 1123–6. doi:10.1016/S0140-6736(83)92864-7. PMID 6133153. S2CID 8303933.

tga.gov.au (Global: 3,984^th place; Korean: 1,245^th place)

“Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017”. 《Therapeutic Goods Administration (TGA)》. 2022년 6월 21일. 2024년 3월 30일에 확인함.

toku-e.com (Global: low place; Korean: low place)

“Tobramycin” (PDF). Toku-E. 2010년 1월 12일. 2012년 6월 11일에 확인함.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“The Top 300 of 2021”. 《ClinCalc》. 2024년 1월 15일에 원본 문서에서 보존된 문서. 2024년 1월 14일에 확인함.

토브라마이신 (Korean Wikipedia)

archive.org (Global: 6th place; Korean: 18th place)

books.google.com (Global: 3rd place; Korean: 9th place)

canada.ca (Global: 1,712th place; Korean: 1,155th place)

clincalc.com (Global: 3,912th place; Korean: 2,490th place)

doi.org (Global: 2nd place; Korean: 3rd place)

dx.doi.org

drugs.com (Global: 399th place; Korean: 141st place)

europa.eu (Global: 68th place; Korean: 145th place)